Impact of surface coating and particle size on the uptake of small and ultrasmall superparamagnetic iron oxide nanoparticles by macrophages

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5415-5421

  Saito, Shigeyoshi ^a   Tsugeno, Mana ^a   Koto, Daichi ^a   Mori, Yuki ^b   Yoshioka, Yoshichika ^b   Nohara, Satoshi ^c   Murase, Kenya ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c Nagoya Research Laboratory   (Japan)

Author keywords

Cultured mouse macrophage cells; MRI; Particle size; Surface coating; Ultrasmall superparamagnetic iron oxide

Indexed keywords

CARBOXYMETHYLDEXTRAN; DEXTRAN MAGNETITE; NANOCOATING; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DENSITY; CELL LABELING; CELL TRANSPORT; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; INCUBATION TIME; INTERNALIZATION; INTRACELLULAR SIGNALING; MACROPHAGE; MOUSE; NANOANALYSIS; NANOCHEMISTRY; NONHUMAN; PARTICLE SIZE; RELAXATION TIME; SURFACE PROPERTY;

COATED MATERIALS, BIOCOMPATIBLE; CONTRAST MEDIA; CRYSTALLIZATION; DEXTRANS; DIFFUSION; MACROMOLECULAR SUBSTANCES; MACROPHAGES; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MATERIALS TESTING; MOLECULAR CONFORMATION; PARTICLE SIZE; SURFACE PROPERTIES;

EID: 84870379722     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S33709     Document Type: Article

References (31)

1. Daldrup-Link HE, Rudelius M, Piontek G, etal. Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-T MR imaging equipment. Radiology. 2005;234(1): 197-205.
2. Murase K, Oonoki J, Takata H, etal. Simulation and experimental studies on magnetic hyperthermia with use of superparamagnetic iron oxide nanoparticles. Radiol Phys Technol. 2011;4(2):194-202.
3. Mori Y, Umeda M, Fukunaga M, Ogasawara K, Yoshioka Y. MR contrast in mouse lymph nodes with subcutaneous administration of iron oxide particles: size dependency. Magn Reson Med Sci. 2011;10(4):219-227.
4. McBain SC, Yiu HH, Dobson J. Magnetic nanoparticles for gene and drug delivery. Int J Nanomedicine. 2008;3(2):169-180.
5. Benderbous S, Corot C, Jacobs P, Bonnemain B. Superparamagnetic agents: physicochemical characteristics and preclinical imaging evaluation. Acad Radiol. 1996;3 Suppl 2:S292-S294.
6. Di Marco M, Sadun C, Port M, Guilbert I, Couvreur P, Dubernet C. Physicochemical characterization of ultrasmall superparamagnetic iron oxide particles (USPIO) for biomedical application as MRI contrast agents. Int J Nanomedicine. 2007;2(4):609-622.
7. Dousset V, Delalande C, Ballarino L, etal. In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance. Magn Reson Med. 1999;41(2):329-333.
8. Josephon L, Tung CH, Moore A, Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem. 1999;10(2):186-191.
9. Stoll G, Wesemeier C, Gold R, Solymosi L, Toyka KV, Bendszus M. In vivo monitoring of macrophage infiltration in experimental autoimmune neuritis by magnetic resonance imaging. J Neuroimmunol. 2004;149(1-2):142-146.
10. Jo SK, Hu X, Kobayashi H, etal. Detection of inflammation following renal ischemia by magnetic resonance imaging. Kidney Int. 2003;64(1): 43-51.
11. Kanno S, Lee PC, Dodd SJ, Williams M, Griffith BP, Ho C. A novel approach with magnetic resonance imaging used for the detection of lung allograft rejection. J Thorac Cardiovasc Surg. 2000;120(5):923-934.
12. Tang T, Howarth SP, Miller SR, etal. Assessment of inflammatory burden contralateral to the symptomatic carotid stenosis using high-resolution ultrasmall, superparamagnetic iron oxide-enhanced MRI. Stroke. 2006;37(9):2266-2270.
13. Trivedi RA, Mallawarachi C, U-King-Im JM, etal. Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol. 2006;26(7): 1601-1606.
14. Weissleder R, Stark DD, Engelstad BL, etal. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol. 1989; 152(1):167-173.
15. Corot C, Robert P, Idee JM, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006; 58(14):1471-1504.
16. Wang YX, Hussain SM, Krestin GP. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol. 2001;11(11):2319-2331.
17. Oishi K, Noguchi H, Saito H, etal. Cell labeling with a novel contrast agent of magnetic resonance imaging. Cell Transplant. 2010; 19(6):887-892.
18. Bowen CV, Zhang X, Saab G, Gareau PJ, Rutt BK. Application of the static dephasing regime theory to superparamagnetic iron-oxide loaded cells. Magn Reson Med. 2002;48(1):52-61.
19. Oude Engberink RD, van der Pol SM, Dopp EA, de Vries HE, Blezer EL. Comparison of SPIO and USPIO for in vitro labeling of human monocytes: MR detection and cell function. Radiology. 2007;243(2):467-474.
20. Matsushita T, Kusakabe Y, Fujii H, Murase K, Yamazaki Y. Inflammatory imaging with ultrasmall superparamagnetic iron oxide. Magn Reson Imaging. 2011;29(2):173-178.
21. Daldrup-Link HE, Rudelius M, Oostendorp RA, etal. Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology. 2003;228(3):760-767.
22. Matuszewski L, Persigehl T, Wall A, etal. Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology. 2005;235(1): 155-161.
23. Weissleder R, Cheng HC, Bogdanova A, Bogdanov A Jr. Magnetically labeled cells can be detected by MR imaging. J Magn Reson Imaging. 1997;7(1):258-263.
24. Schoepf U, Marecos EM, Melder RJ, Jain RK, Weissleder R. Intracellular magnetic labeling of lymphocytes for in vivo trafficking studies. Biotechniques. 1998;24(4):642-646, 648-651.
25. Frank JA, Miller BR, Arbab AS, etal. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology. 2003;228(2):480-487.
26. Wunderbaldinger P, Josephon L, Weissleder R. Tat peptide directs enhanced clearance and hepatic permeability of magnetic nanoparticles. Bioconjug Chem. 2002;13(2):264-268.
27. Bulte JW, Kraitchman DL. Iron oxide MR contrast agents for molecular and cellular imaging. NMR Biomed. 2004;17(7):484-499.
28. Bulte JW, Vymazal J, Brooks RA, Pierpaoli C, Frank JA. Frequency dependence of MR relaxation times. II. Iron oxides. J Magn Reson Imaging. 1993;3(4):641-648.
29. Zhu XM, Wang YX, Leung KC, etal. Enhanced cellular uptake of aminosilane-coated superparamagnetic iron oxide nanoparticles in mammalian cell lines. Int J Nanomedicine. 2012;7:953-964.
30. Kunzmann A, Andersson B, Vogt C, etal. Efficient internalization of silica-coated iron oxide nanoparticles of different sizes by primary human macrophages and dendritic cells. Toxicol Appl Pharmacol. 2011; 253(2):81-93.
31. Majumdar S, Zoghbi SS, Gore JC. Pharmacokinetics of superparamagnetic iron-oxide MR contrast agents in the rat. Invest Radiol. 1990;25(7): 771-777.